6 completed, 2 active not recruiting, 2 recruiting, 1 terminated. 5 Phase 1, 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Terminated 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
| Not applicable | 1 | Active not recruiting 1 |
Follow Primary Mediastinal B-Cell Lymphoma: new trials by email Literature Review of Primary Mediastinal B-Cell Lymphoma trials Research Report on Primary Mediastinal B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Non-Hodgkin Lymphoma, T-Cell Lymphoma | Recruiting | Natera, Inc. | 200 | 2026-07-27 | 2026-08-06 | |
| Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells ADI-001 - Lymphoma, Follicular, Lymphoma, Mantle-Cell | Active not recruiting | Adicet Therapeutics | 50 | 2022-02-14 | 2026-04-09 | |
| A Phase 1 Study of ADI-001 in B Cell Malignancies ADI-001, Fludarabine, Cyclophosphamide - Lymphoma, Follicular, Lymphoma, Mantle-Cell | Phase 1 | Terminated | Adicet Therapeutics | 34 | 2021-03-04 | 2025-06-18 |
| Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) ADCT-402 - Non-Hodgkin Lymphoma, Burkitt's Lymphoma | Phase 1 | Completed | ADC Therapeutics S.A. | 183 | 2016-03-01 | 2021-05-19 |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) JCAR017 (lisocabtagene maraleucel) single-dose schedule, JCAR017 (lisocabtagene maraleucel) 2-dose schedule - Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Phase 1 | Completed | Juno Therapeutics, a Subsidiary of Celgene | 387 | 2016-01-06 | 2024-06-27 |
| Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL Obinutuzumab, Liposomal ARA-C, Ifosfamide - Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | New York Medical College | 25 | 2015-08-21 | 2026-10-23 |
| A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) Pembrolizumab, Lenalidomide 20 mg, Lenalidomide 25 mg - Myelodysplastic Syndrome, Multiple Myeloma | Phase 1 | Completed | Merck Sharp & Dohme LLC | 197 | 2013-11-22 | 2021-08-04 |
| Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma observation, 3D-Conformal Radiotherapy (3D-CRT) - Primary Mediastinal B-cell Lymphoma | Not applicable | Active not recruiting | International Extranodal Lymphoma Study Group (IELSG) | 540 | 2012-10-01 | 2026-01-15 |
| CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma Fludarabine, Cyclophosphamide, Anti-cluster of differentiation 19 (CD19)-CAR PBL - Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2009-02-17 | 2022-01-12 |
| A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma Primary Mediastinal B-Cell Lymphoma | Completed | International Extranodal Lymphoma Study Group (IELSG) | 125 | 2007-01-01 | 2017-08-15 | |
| R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas immunotherapy, Induction treatment part 1, Induction treatment part 2 with PBPC collection - Diffuse Large B-Cell Lymphoma., Primary Mediastinal B-Cell Lymphoma | Phase 2 | Completed | Czech Lymphoma Study Group | 106 | 2002-05-01 | 2007-11-14 |
Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Follicular (7) · Lymphoma, Non-Hodgkin (7) · Lymphoma, Mantle-Cell (4) · Lymphoma, B-Cell (3) · Burkitt Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Hodgkin Disease (1) · Leukemia (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Peripheral (1)
Hemic and Lymphatic Diseases (9) · Immune System Diseases (9) · Immunoproliferative Disorders (9) · Lymphatic Diseases (9) · Lymphoproliferative Disorders (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Lymphoma (7) · Lymphoma, B-Cell (5) · Hematologic Diseases (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Chronic Disease (2) · DNA Virus Infections (2) · Disease Attributes (2)
Cyclophosphamide (2) · fludarabine (2) · Appointments and Schedules (1) · Carboplatin (1) · Etoposide (1) · Ifosfamide (1) · Immunotherapy (1) · Interleukin-2 (1) · Lenalidomide (1) · Observation (1) · Radiotherapy, Conformal (1) · aldesleukin (1) · fludarabine phosphate (1) · loncastuximab tesirine (1) · obinutuzumab (1)
Adicet Therapeutics (2) · International Extranodal Lymphoma Study Group (IELSG) (2) · ADC Therapeutics S.A. (1) · Czech Lymphoma Study Group (1) · Juno Therapeutics, a Subsidiary of Celgene (1) · Merck Sharp & Dohme LLC (1) · Natera, Inc. (1) · National Cancer Institute (NCI) (1) · New York Medical College (1)
United States (8) · Italy (3) · United Kingdom (3) · Czechia (2) · Switzerland (2) · Argentina (1) · Canada (1) · China (1) · Germany (1) · Norway (1) · Poland (1) · Portugal (1) · Spain (1) · Sweden (1) · Ukraine (1)
Alberto Biggi, MD (1) · Andrew J Davies, MD (1) · Annibale Versari, MD (1) · Gianni Ciccone, MD (1) · Luca Ceriani, MD (1) · Mary Gospodarowicz, MD (1) · Maurizio Martelli, MD (1) · Mitchell Cairo, MD (1) · Pytlik Robert, M.D. (1) · Sally F Barrington, MD (1) · Steven A Rosenberg, M.D., Ph.D. (1)
PMID 34515338, PMID 20668228, PMID 22160384, PMID 23546520, PMID 24055823, PMID 24799481, PMID 25154820, PMID 26089397, PMID 27354476, PMID 28291388, PMID 28490569, PMID 28803861, PMID 29720487, PMID 29895668, PMID 30937889, PMID 31395089, PMID 31609651, PMID 31685491, PMID 32556281, PMID 32871584, PMID 32888407, PMID 33021872, PMID 33211842, PMID 33720336, PMID 33904895, PMID 33970454, PMID 34125421, PMID 34310745, PMID 34493319, PMID 34893942, PMID 35136603, PMID 35156195, PMID 35244520, PMID 35337365, PMID 35610089, PMID 36398795, PMID 36755418, PMID 37890149, PMID 38072625, PMID 39159403, PMID 40939190, PMID 42237652
2016 (1)